Paper Details

  1. Home
  2. Paper Details

Sulphasalazine in ankylosing spondylitis. A radiological, clinical and laboratory assessment.

Author: BeswickE J, DawesP T, TaylorH G

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

A 12-month study of 40 patients with ankylosing spondylitis compared sulphasalazine to a placebo. While both groups showed improvement in some symptoms (pain, stiffness, sleep disturbance, and certain inflammatory markers), sulphasalazine had a significantly greater impact on these measures. However, neither treatment slowed the progression of joint damage as assessed by X-ray and CT scans. Ultimately, the study found no significant difference in overall disease activity between the sulphasalazine and placebo groups.
Paper Details　
Original Abstract of the Article :
In a 12-month double-blind placebo-controlled trial, the effect of sulphasalazine was studied in 40 patients with ankylosing spondylitis. The treatment group showed significant improvement in pain, stiffness, sleep disturbance (p less than 0.05), finger/floor distance, erythrocyte sedimentation rate...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/BF02208032

データ提供：米国国立医学図書館（NLM）

Sulphasalazine: A Potential Treatment for Ankylosing Spondylitis

Ankylosing spondylitis (AS) is a chronic inflammatory disease that affects the spine, much like a desert wind eroding a delicate rock formation. This study investigates the efficacy of sulphasalazine in treating AS, comparing it to placebo in a double-blind, controlled trial. The authors found that sulphasalazine improved pain, stiffness, and other disease indicators, but it did not significantly retard radiological progression.

Sulphasalazine: A Modest Improvement in Ankylosing Spondylitis

This study provides evidence for the potential benefits of sulphasalazine in managing AS. The authors found that sulphasalazine led to significant improvements in pain, stiffness, and other disease indicators, offering relief to patients. However, the study also showed that sulphasalazine did not significantly retard radiological progression, suggesting that it may not prevent long-term structural damage. The authors call for further research to explore the role of sulphasalazine in AS management.

Navigating the Sands of Ankylosing Spondylitis

This research provides valuable insights for individuals seeking treatment for AS. While sulphasalazine showed promise in improving pain and stiffness, the study highlights the ongoing challenge of finding treatments that can effectively prevent long-term structural damage. The authors encourage further research to develop more effective therapies for AS, offering a path to better health and well-being for those affected by this chronic condition.

Dr. Camel's Conclusion

This study provides mixed results regarding the efficacy of sulphasalazine in treating ankylosing spondylitis. While it showed promise in reducing pain and stiffness, it did not significantly retard radiological progression. Further research is needed to explore the role of sulphasalazine in managing this chronic inflammatory disease and to develop more effective therapies that can prevent long-term structural damage.

Date :
  1. Date Completed 1991-08-15
  2. Date Revised 2019-09-07
Further Info :

Pubmed ID

1676621

DOI: Digital Object Identifier

10.1007/BF02208032

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.